The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a greater substantial reductio